Cephalexin

CAS No:
15686-71-2 Category:
  • #LGM Pharma is a Cephalexin CAS# 15686-71-2 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 15686-71-2
  • AHFC code: 08:12.06.04
  • Synonyms: Cefalessina [DCIT] Cefalexin Cefalexin Sodium Cefalexina [INN-Spanish] Cefalexine [INN-French] Cefalexinum [INN-Latin] Cephalexin 1-hydrate Cephalexin hydrate Cephalexin monohydrate Cephalexine Cephalexinum CEX
  • ATC Code: J01DB01
  • Chemical Formula: C23H29ClFN3O4
  • Molecular Weight: 347.389
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB00567 (APRD00250)
  • SMILES: CC1=C(N2[C,H](SC1)[C,H](NC(=O)[C,H](N)C1=CC=CC=C1)C2=O)C(O)=O
  • InChl: ZAIPMKNFIOOWCQ-UEKVPHQBSA-N
  • PubChem: 2666
  • IUPAC: (6R,7R)-7-[(2R)-2-amino-2-phenylacetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

Additional Details

Indication:
For the treatment of respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes; otitis media due to Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, and Moraxella catarrhalis; skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes; bone infections caused by Staphylococcus aureus and/or Proteus mirabilis; genitourinary tract infections, including acute prostatitis, caused by Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae.
Pharmacodynamics:
Cephalexin (also called Cefalexin) is a first generation cephalosporin antibiotic. It is one of the most widely prescribed antibiotics, often used for the treatment of superficial infections that result as complications of minor wounds or lacerations. It is effective against most gram-positive bacteria.
Mode of Action:
Cephalexin, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cephalexin interferes with an autolysin inhibitor.
Metabolism:
No appreciable biotransformation in the liver (90% of the drug is excreted unchanged in the urine).
Toxicity:
Symptoms of overdose include blood in the urine, diarrhea, nausea, upper abdominal pain, and vomiting. The oral median lethal dose of cephalexin in rats is >5000 mg/kg.
General Reference:
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials

 

Related YouTube Videos